Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hua

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
The American Journal of Cardiology|December 16, 2011
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertensionStevo Julius, Paolo Palatini, Sverre E Kjeldsen, et al.
Molecular Genetics and Genomics : MGG|July 8, 2003
Gene content and organization of an 85-kb DNA segment from the genome of the phytopathogenic mollicute Spiroplasma kunkeliiY Zhao, R W Hammond, R Jomantiene, et al.
Kidney International|December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular riskMatthew R Weir, George L Bakris, Michael A Weber, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 29, 2017
Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
JACC. Heart Failure|April 4, 2016
Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF TrialPeter S Pang, John R Teerlink, Adriaan A Voors, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 3, 2017
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
Human Molecular Genetics|March 1, 1997
Disruption of the clathrin heavy chain-like gene (CLTCL) associated with features of DGS/VCFS: a balanced (21;22)(p12;q11) translocationS E Holmes, M A Riazi, W Gong, et al.
American Heart Journal|April 30, 2017
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trialPeter S Pang, John R Teerlink, Leandro Boer-Martins, et al.
Blood Pressure|July 9, 2008
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialSverre E Kjeldsen, Gordon T McInnes, Giuseppe Mancia, et al.
European Journal of Heart Failure|April 29, 2017
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 studyJohn R Teerlink, Adriaan A Voors, Piotr Ponikowski, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
The American Journal of Cardiology|December 16, 2011
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertensionStevo Julius, Paolo Palatini, Sverre E Kjeldsen, et al.
Molecular Genetics and Genomics : MGG|July 8, 2003
Gene content and organization of an 85-kb DNA segment from the genome of the phytopathogenic mollicute Spiroplasma kunkeliiY Zhao, R W Hammond, R Jomantiene, et al.
Kidney International|December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular riskMatthew R Weir, George L Bakris, Michael A Weber, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 29, 2017
Erratum to: Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
JACC. Heart Failure|April 4, 2016
Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF TrialPeter S Pang, John R Teerlink, Adriaan A Voors, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 3, 2017
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
Human Molecular Genetics|March 1, 1997
Disruption of the clathrin heavy chain-like gene (CLTCL) associated with features of DGS/VCFS: a balanced (21;22)(p12;q11) translocationS E Holmes, M A Riazi, W Gong, et al.
American Heart Journal|April 30, 2017
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trialPeter S Pang, John R Teerlink, Leandro Boer-Martins, et al.
Blood Pressure|July 9, 2008
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialSverre E Kjeldsen, Gordon T McInnes, Giuseppe Mancia, et al.
European Journal of Heart Failure|April 29, 2017
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 studyJohn R Teerlink, Adriaan A Voors, Piotr Ponikowski, et al.
Pageof 11